Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009160 | 0.73 | CA12 (0.44) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL16738670 | 0.71 | PDE2A (0.50) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL24401545 | 0.71 | GAA (0.47) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL6068563 | 0.69 | MAPK1 (0.48) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL31211064 | 0.68 | GAA (0.52) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL9650033 | 0.68 | ADORA3 (0.58) | GAAKDM4EALDH1A1GABRA2GABRB2 | |
| SCHEMBL7517896 | 0.68 | ADORA3 (0.61) | GAAPOLBGABRA2GABRB2ADORA3 | |
| SCHEMBL30748698 | 0.68 | ADORA3 (0.61) | GAAPOLBGABRA2GABRB2ADORA3 | |
| SCHEMBL21236325 | 0.68 | GAA (0.46) | GAAKDM4EPOLBCYP1A2ALDH1A1 | |
| SCHEMBL13732825 | 0.67 | GAA (0.58) | GAAKDM4EPOLBCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | GAA 1485/4885KDM4E 1460/4885POLB 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.